Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 5/20 | 0.57 |
| ▸ | ALPL | P05186 | 4/20 | 0.57 |
| ▸ | ALPG | P10696 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | RECQL | P46063 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396323 | 1.00 | MAPT (0.60) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL21951986 | 0.88 | MAPT (0.71) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL21952028 | 0.88 | HPGD (0.57) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL31396326 | 0.88 | HPGD (0.57) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209682 | 0.84 | MAPT (0.71) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL21952080 | 0.84 | HPGD (0.58) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL30296021 | 0.83 | CPB1 (0.48) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209664 | 0.82 | ALPL (0.73) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209657 | 0.82 | MAPT (0.82) | MAPTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209661 | 0.82 | MAPT (0.64) | MAPTHPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880199-B1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACION PUBLICA GALLEGA DE INVESTIG BIOMEDICA INIBIC (ES) | 2025-04-23 | — | — | EP | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020099652-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2020-05-22 | — | — | WO | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | MAPT 1710/4885HPGD 2761/4885KMT2A 663/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | MAPT 3296/4885HPGD 1570/4885KMT2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.